Logistic regression model evaluating relation of laboratory parameters with cerebral infarction
| . | OR . | aOR . | ||||
|---|---|---|---|---|---|---|
| Cerebral infarction . | OR . | 95% CI . | P . | OR . | 95% CI . | P . |
| Pediatric cohort | ||||||
| PoS (10 mmHg ↑) | 1.77 | 1.00-3.12 | .054 | 1.80 | 0.98-3.31 | .058 |
| EImin (0.1 EI ↑) | 0.39 | 0.18-0.86 | .020 | 0.53 | 0.23-1.21 | .135 |
| EImax (0.1 EI ↑) | 0.42 | 0.24-0.73 | .002∗ | 0.47 | 0.27-0.83 | .011 |
| Blood viscosity (1.0 cP ↑)† | 0.75 | 0.35-1.60 | .453 | 0.61 | 0.28-1.34 | .218 |
| HVR | 1.76 | 0.70-4.42 | .231 | 1.97 | 0.77-5.04 | .157 |
| Hb (1.0 g/dL ↑) | 0.90 | 0.61-1.35 | .619 | 0.89 | 0.59-1.32 | .552 |
| HbF (10.0% ↑)‡ | 0.77 | 0.30-2.01 | .602 | 1.09 | 0.37-3.22 | .869 |
| MCV (10 fl ↑) | 1.01 | 0.66-1.55 | .961 | 0.94 | 0.63-1.39 | .774 |
| MCHC (1.0 g/dL ↑) | 0.87 | 0.61-1.24 | .444 | 0.88 | 0.62-1.24 | .465 |
| MCH (10.0 pg ↑) | 0.75 | 0.20-2.78 | .670 | 0.68 | 0.18-2.62 | .572 |
| ARC (100 × 109/L ↑) | 1.29 | 0.91-1.83 | .147 | 1.25 | 0.86-1.82 | .237 |
| DRBCs (1.0% ↑) | 1.23 | 1.07-1.42 | .004∗ | 1.19 | 1.01-1.40 | .038 |
| Adult cohort | ||||||
| PoS (10 mmHg ↑) | 3.13 | 0.96-10.14 | .058 | 3.25 | 0.86-12.34 | .080 |
| EImin (0.1 EI ↑) | 0.15 | 0.14-1.56 | .112 | 0.07 | 0.00-2.11 | .125 |
| EImax (0.1 EI ↑) | 0.23 | 0.04-1.16 | .074 | 0.18 | 0.19-1.62 | .126 |
| Blood viscosity (1.0 cP ↑) | n/a | n/a | n/a | n/a | n/a | n/a |
| HVR | n/a | n/a | n/a | n/a | n/a | n/a |
| Hb (1.0 g/dL ↑) | 0.77 | 0.31-1.94 | .581 | 0.78 | 0.29-2.08 | .613 |
| HbF (10.0% ↑) | 0.12 | 0.00-3.20 | .204 | 0.06 | 0.00-4.03 | .188 |
| MCV (10 fl ↑) | 0.82 | 0.37-1.83 | .630 | 1.02 | 0.36-2.88 | .970 |
| MCHC (1 g/dL ↑) | 1.33 | 0.52-3.42 | .551 | 1.39 | 0.53-3.68 | .508 |
| MCH (1.0 pg ↑) | 1.03 | 0.87-1.22 | .778 | 1.13 | 0.87-1.44 | .385 |
| ARC (100 × 109/L ↑) | 1.02 | 0.92-1.15 | .679 | 1.00 | 0.89-1.13 | .973 |
| DRBCs (1.0% ↑) | n/a | n/a | n/a | n/a | n/a | n/a |
| . | OR . | aOR . | ||||
|---|---|---|---|---|---|---|
| Cerebral infarction . | OR . | 95% CI . | P . | OR . | 95% CI . | P . |
| Pediatric cohort | ||||||
| PoS (10 mmHg ↑) | 1.77 | 1.00-3.12 | .054 | 1.80 | 0.98-3.31 | .058 |
| EImin (0.1 EI ↑) | 0.39 | 0.18-0.86 | .020 | 0.53 | 0.23-1.21 | .135 |
| EImax (0.1 EI ↑) | 0.42 | 0.24-0.73 | .002∗ | 0.47 | 0.27-0.83 | .011 |
| Blood viscosity (1.0 cP ↑)† | 0.75 | 0.35-1.60 | .453 | 0.61 | 0.28-1.34 | .218 |
| HVR | 1.76 | 0.70-4.42 | .231 | 1.97 | 0.77-5.04 | .157 |
| Hb (1.0 g/dL ↑) | 0.90 | 0.61-1.35 | .619 | 0.89 | 0.59-1.32 | .552 |
| HbF (10.0% ↑)‡ | 0.77 | 0.30-2.01 | .602 | 1.09 | 0.37-3.22 | .869 |
| MCV (10 fl ↑) | 1.01 | 0.66-1.55 | .961 | 0.94 | 0.63-1.39 | .774 |
| MCHC (1.0 g/dL ↑) | 0.87 | 0.61-1.24 | .444 | 0.88 | 0.62-1.24 | .465 |
| MCH (10.0 pg ↑) | 0.75 | 0.20-2.78 | .670 | 0.68 | 0.18-2.62 | .572 |
| ARC (100 × 109/L ↑) | 1.29 | 0.91-1.83 | .147 | 1.25 | 0.86-1.82 | .237 |
| DRBCs (1.0% ↑) | 1.23 | 1.07-1.42 | .004∗ | 1.19 | 1.01-1.40 | .038 |
| Adult cohort | ||||||
| PoS (10 mmHg ↑) | 3.13 | 0.96-10.14 | .058 | 3.25 | 0.86-12.34 | .080 |
| EImin (0.1 EI ↑) | 0.15 | 0.14-1.56 | .112 | 0.07 | 0.00-2.11 | .125 |
| EImax (0.1 EI ↑) | 0.23 | 0.04-1.16 | .074 | 0.18 | 0.19-1.62 | .126 |
| Blood viscosity (1.0 cP ↑) | n/a | n/a | n/a | n/a | n/a | n/a |
| HVR | n/a | n/a | n/a | n/a | n/a | n/a |
| Hb (1.0 g/dL ↑) | 0.77 | 0.31-1.94 | .581 | 0.78 | 0.29-2.08 | .613 |
| HbF (10.0% ↑) | 0.12 | 0.00-3.20 | .204 | 0.06 | 0.00-4.03 | .188 |
| MCV (10 fl ↑) | 0.82 | 0.37-1.83 | .630 | 1.02 | 0.36-2.88 | .970 |
| MCHC (1 g/dL ↑) | 1.33 | 0.52-3.42 | .551 | 1.39 | 0.53-3.68 | .508 |
| MCH (1.0 pg ↑) | 1.03 | 0.87-1.22 | .778 | 1.13 | 0.87-1.44 | .385 |
| ARC (100 × 109/L ↑) | 1.02 | 0.92-1.15 | .679 | 1.00 | 0.89-1.13 | .973 |
| DRBCs (1.0% ↑) | n/a | n/a | n/a | n/a | n/a | n/a |
A logistic regression analysis was performed to calculate ORs for oxygen gradient ektacytometry–derived parameters, blood viscosity, DRBCs, HbF, and hemocytometry parameters in relation to occurrence of cerebral infarction. aORs were corrected for age and hydroxyurea therapy.
Abbreviations are explained in Table 3.
OR is significant after correcting for multiple testing (false discovery rate analysis).
Data of 110 individuals available.
Data of 90 individuals available.